FDA & Clinical Trials
Coverage of FDA decisions, drug approvals, trial results, regulatory updates, and major healthcare milestones affecting biotech companies.
Biotech Market News
Reporting on biotech stock activity, earnings, partnerships, financings, mergers, acquisitions, and market-moving developments.
Healthcare Technology
News and analysis covering medical technology, AI in healthcare, diagnostics, genomics, digital health, and emerging biotech innovation.
Pharmaceuticals
Coverage focused on drug development, treatments, vaccines, oncology, rare diseases, and advances in pharmaceutical research.
Industry & Research
Articles exploring scientific discoveries, biotechnology trends, academic research, manufacturing advances, and the broader biotech landscape.
Latest Articles
-
What Is the Difference Between an NDA and a BLA? The Two Paths to FDA Drug Approval
When a biotech or pharmaceutical company completes its clinical trial program and is ready to ask the FDA for approval, it faces a fundamental fork in the road: file a… Continue Reading
-
What Is Orphan Drug Designation? The FDA Program That Transformed Rare Disease Drug Development
For investors in clinical-stage biotech companies, few regulatory announcements are as consistently positive as an Orphan Drug Designation from the FDA. The designation signals that a drug targets a rare… Continue Reading
-
What Is AI in Drug Discovery? How Machine Learning Is Reshaping Biotech
Artificial intelligence has become one of the most discussed and most misunderstood concepts in the biotech sector. Some companies claim AI will compress the 15-year drug discovery timeline to a… Continue Reading
-
What Is CRISPR? Gene Editing Technology and Its Biotech Investment Implications
In 2020, Emmanuelle Charpentier and Jennifer Doudna were awarded the Nobel Prize in Chemistry for developing CRISPR-Cas9 — a gene editing technology that has been described as one of the… Continue Reading
-
What Is a Complete Response Letter (CRL)? The FDA’s Most Feared Document Explained
The three letters that biotech investors most dread seeing on a PDUFA date are CRL. A Complete Response Letter from the FDA means the agency has reviewed the drug application… Continue Reading
-
What Is a Binary Event in Biotech? High-Stakes Catalysts Explained
Few events in the financial markets generate the kind of violent, same-day price moves that biotech binary events produce. A Phase 3 trial result, an FDA approval decision, or an… Continue Reading
-
What Is Cash Runway in Biotech? How to Evaluate a Company’s Financial Health
Most clinical-stage biotech companies generate no revenue. They spend money — sometimes enormous amounts of it — running trials and paying staff, while waiting on FDA decisions that may be… Continue Reading
-
How Does the FDA Drug Approval Process Work? A Complete Guide for Investors
The path from a molecule in a laboratory to an FDA-approved drug available to patients is one of the most complex, expensive, and high-stakes journeys in modern science. On average,… Continue Reading